source
- Merck and Daiichi Sankyo pull accelerated approval request for lung cancer ADCMerck and Daiichi Sankyo have voluntarily withdrawn their application for accelerated approval of the antibody-drug conjugate ifinatamab deruxtecan. The FDA indicated that the data package did not…
- Scynexis secures $214 million BARDA contract to advance oral and IV antifungal SCY-247BARDA awarded Scynexis a $214 million contract to develop a treatment for invasive fungal infections, including an upfront payment of about $18.5 million. The funding will support moving SCY-247,…